



Bethkis® (tobramycin) – First-time generic and authorized brand alternative

- On September 16, 2020, [Teva launched](#) an [AB-rated](#) generic version and [Prasco launched](#) an authorized brand alternative of Chiesi's [Bethkis \(tobramycin\)](#) inhalation solution 300 mg/4 mL.
- Bethkis is approved for the management of cystic fibrosis patients with *Pseudomonas aeruginosa*.
- Tobramycin inhalation solution [300 mg/5 mL](#) is also available generically and carries the same indication as Bethkis.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.